IZA DP No. 16653: Revisiting the OxyContin Reformulation: The Role of Licit Substitutes
Francis W. Graham, Sonja C. de New, Suzanne Nielsen, Dennis Petrie
After the introduction of abuse-deterrent OxyContin in 2010, states with widespread extramedical OxyContin use experienced steep increases in heroin deaths, implying substitution from OxyContin to heroin. Leveraging cross-state variation in initial OxyContin utilization, we show the OxyContin reformulation also induced substitution to a similar prescription opioid product, Opana ER. States with high Opana ER utilization after the OxyContin reformulation experienced continued growth in prescription opioid deaths, and after Opana ER was reformulated 18 months later, an additional wave of substitution to heroin previously solely attributed to OxyContin. Our results highlight underappreciated substitution pathways throughout these pivotal years of the epidemic.
We use cookies to provide you with an optimal website experience. This includes cookies that are necessary for the operation of the site as well as cookies that are only used for anonymous statistical purposes, for comfort settings or to display personalized content. You can decide for yourself which categories you want to allow. Please note that based on your settings, you may not be able to use all of the site's functions.
Cookie settings
These necessary cookies are required to activate the core functionality of the website. An opt-out from these technologies is not available.
In order to further improve our offer and our website, we collect anonymous data for statistics and analyses. With the help of these cookies we can, for example, determine the number of visitors and the effect of certain pages on our website and optimize our content.